Blood-based biomarkers in mild behavioral impairment: an updated overview
Identifying individuals at-risk for dementia is one of the critical objectives of current research efforts, highlighting the need for simple, cost-effective, and minimally invasive biomarkers. Mild behavioral impairment (MBI), characterized by the emergence of persistent neuropsychiatric manifestati...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2025.1534193/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832087423002083328 |
|---|---|
| author | Efthalia Angelopoulou Xenia Androni Chiara Villa Alexandros Hatzimanolis Nikolaos Scarmeas Sokratis Papageorgiou |
| author_facet | Efthalia Angelopoulou Xenia Androni Chiara Villa Alexandros Hatzimanolis Nikolaos Scarmeas Sokratis Papageorgiou |
| author_sort | Efthalia Angelopoulou |
| collection | DOAJ |
| description | Identifying individuals at-risk for dementia is one of the critical objectives of current research efforts, highlighting the need for simple, cost-effective, and minimally invasive biomarkers. Mild behavioral impairment (MBI), characterized by the emergence of persistent neuropsychiatric manifestations in older adults, has attracted increasing attention as a potential early indicator of cognitive decline and dementia. A growing number of studies have recently begun to explore the relationship between MBI and several blood-based biomarkers associated with Alzheimer’s disease (AD) pathology, neurodegeneration, as well as systemic metabolic and inflammatory dysregulation. In this context, MBI has been associated with lower plasma Aβ42/Αβ40 ratio, higher plasma phosphorylated tau at threonine 181 (p-tau181), increased neurofilament light chain (NfL) levels, as well as disturbances in metabolic markers, including homocysteine, insulin and ferritin, suggesting a multifaceted neurobiological basis for this syndrome. These findings offer insights into the underlying pathophysiology of MBI, and connection between neuropsychiatric symptoms and progression of AD. In this narrative review, we aim to summarize and critically discuss the emerging literature evidence linking MBI to blood-based biomarkers, hoping to shed more light on MBI’s pathophysiology, its connection to AD-related neurobiology, as well as its potential practical utility for predicting cognitive impairment, guiding early interventions and managing the risk for dementia. |
| format | Article |
| id | doaj-art-cc0a2e7bd0004e689efaed1884ffc744 |
| institution | Kabale University |
| issn | 1664-2295 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj-art-cc0a2e7bd0004e689efaed1884ffc7442025-02-06T05:21:42ZengFrontiers Media S.A.Frontiers in Neurology1664-22952025-02-011610.3389/fneur.2025.15341931534193Blood-based biomarkers in mild behavioral impairment: an updated overviewEfthalia Angelopoulou0Xenia Androni1Chiara Villa2Alexandros Hatzimanolis3Nikolaos Scarmeas4Sokratis Papageorgiou51st Department of Neurology, Aiginiteio University Hospital, National and Kapodistrian University of Athens, Athens, Greece1st Department of Neurology, Aiginiteio University Hospital, National and Kapodistrian University of Athens, Athens, GreeceSchool of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy1st Department of Psychiatry, Aiginiteio University Hospital, National and Kapodistrian University of Athens, Athens, Greece1st Department of Neurology, Aiginiteio University Hospital, National and Kapodistrian University of Athens, Athens, Greece1st Department of Neurology, Aiginiteio University Hospital, National and Kapodistrian University of Athens, Athens, GreeceIdentifying individuals at-risk for dementia is one of the critical objectives of current research efforts, highlighting the need for simple, cost-effective, and minimally invasive biomarkers. Mild behavioral impairment (MBI), characterized by the emergence of persistent neuropsychiatric manifestations in older adults, has attracted increasing attention as a potential early indicator of cognitive decline and dementia. A growing number of studies have recently begun to explore the relationship between MBI and several blood-based biomarkers associated with Alzheimer’s disease (AD) pathology, neurodegeneration, as well as systemic metabolic and inflammatory dysregulation. In this context, MBI has been associated with lower plasma Aβ42/Αβ40 ratio, higher plasma phosphorylated tau at threonine 181 (p-tau181), increased neurofilament light chain (NfL) levels, as well as disturbances in metabolic markers, including homocysteine, insulin and ferritin, suggesting a multifaceted neurobiological basis for this syndrome. These findings offer insights into the underlying pathophysiology of MBI, and connection between neuropsychiatric symptoms and progression of AD. In this narrative review, we aim to summarize and critically discuss the emerging literature evidence linking MBI to blood-based biomarkers, hoping to shed more light on MBI’s pathophysiology, its connection to AD-related neurobiology, as well as its potential practical utility for predicting cognitive impairment, guiding early interventions and managing the risk for dementia.https://www.frontiersin.org/articles/10.3389/fneur.2025.1534193/fullMild behavioral impairmentbiomarkersAlzheimer’s diseasedementianeuropsychiatric symptoms |
| spellingShingle | Efthalia Angelopoulou Xenia Androni Chiara Villa Alexandros Hatzimanolis Nikolaos Scarmeas Sokratis Papageorgiou Blood-based biomarkers in mild behavioral impairment: an updated overview Frontiers in Neurology Mild behavioral impairment biomarkers Alzheimer’s disease dementia neuropsychiatric symptoms |
| title | Blood-based biomarkers in mild behavioral impairment: an updated overview |
| title_full | Blood-based biomarkers in mild behavioral impairment: an updated overview |
| title_fullStr | Blood-based biomarkers in mild behavioral impairment: an updated overview |
| title_full_unstemmed | Blood-based biomarkers in mild behavioral impairment: an updated overview |
| title_short | Blood-based biomarkers in mild behavioral impairment: an updated overview |
| title_sort | blood based biomarkers in mild behavioral impairment an updated overview |
| topic | Mild behavioral impairment biomarkers Alzheimer’s disease dementia neuropsychiatric symptoms |
| url | https://www.frontiersin.org/articles/10.3389/fneur.2025.1534193/full |
| work_keys_str_mv | AT efthaliaangelopoulou bloodbasedbiomarkersinmildbehavioralimpairmentanupdatedoverview AT xeniaandroni bloodbasedbiomarkersinmildbehavioralimpairmentanupdatedoverview AT chiaravilla bloodbasedbiomarkersinmildbehavioralimpairmentanupdatedoverview AT alexandroshatzimanolis bloodbasedbiomarkersinmildbehavioralimpairmentanupdatedoverview AT nikolaosscarmeas bloodbasedbiomarkersinmildbehavioralimpairmentanupdatedoverview AT sokratispapageorgiou bloodbasedbiomarkersinmildbehavioralimpairmentanupdatedoverview |